The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...

Companies don’t generally cut prices out of generosity.

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...

Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that ...